<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416754</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000450754</org_study_id>
    <secondary_id>R01CA082346</secondary_id>
    <secondary_id>P30CA051008</secondary_id>
    <secondary_id>GUMC-2000-305</secondary_id>
    <nct_id>NCT00416754</nct_id>
  </id_info>
  <brief_title>Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations</brief_title>
  <official_title>Improving the Long-Term Outcomes of BRCA1/BRCA2 Mutation Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Genetic counseling and using an interactive computer program may help women at&#xD;
      risk for breast cancer make medical decisions about treatment.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying standard genetic counseling to see how&#xD;
      well it works when given together with or without a medical decision-making computer program&#xD;
      in women at risk for BRCA1 or BRCA2 mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the impact of BRCA1/BRCA2 testing among members of hereditary breast-ovarian&#xD;
           cancer families.&#xD;
&#xD;
        -  Evaluate the long-term impact of genetic counseling and testing on psychosocial and&#xD;
           behavioral outcomes.&#xD;
&#xD;
        -  Evaluate the relative impact of standard genetic counseling (SGC) versus SGC plus the&#xD;
           interactive decision-aid (IDA) on medical decision-making.&#xD;
&#xD;
        -  Evaluate the relative impact of SGC vs SGC + IDA on psychological well-being.&#xD;
&#xD;
        -  Explore the mechanisms by which the SGC + IDA intervention impacts on psychosocial and&#xD;
           behavioral outcomes.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Eligible women are asked to participate in a baseline telephone interview over 30 minutes and&#xD;
      then invited to a genetic counseling session over 1.5-2 hours that includes information about&#xD;
      BRCA1/2 testing. Patients are then offered BRCA1/2 testing, and the test results (i.e.,&#xD;
      mutation carrier vs noncarrier) are presented at a subsequent in-person individual genetic&#xD;
      counseling session over 1.5-2 hours. Patients who tested positive for BRCA1 or 2 mutation are&#xD;
      randomized to 1 of 2 counseling arms. All other patients proceed to follow up.&#xD;
&#xD;
        -  Arm I (standard genetic counseling): No further counselor-initiated contact is&#xD;
           scheduled.&#xD;
&#xD;
        -  Arm II (individualized decision aid): Patients are asked to view an interactive computer&#xD;
           program that is designed to help the patients make medical decisions based on their&#xD;
           breast cancer risk.&#xD;
&#xD;
      Outcome assessments, including quality of life assessment, are conducted at 2, 6, and 12&#xD;
      months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 950 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>1 year</time_frame>
    <description>subjects will complete questionnaires re; genetic counseling experience</description>
  </primary_outcome>
  <enrollment type="Actual">1109</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>counseling intervention</intervention_name>
    <description>subjects will receive genetic counseling</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Members of hereditary breast/ovarian cancer families (in which there is at least a&#xD;
             10-20% prior probability of a BRCA1/2 mutation) OR who have a first-degree relative&#xD;
             with a known BRCA1 or BRCA2 mutation&#xD;
&#xD;
          -  Prior diagnosis of breast cancer allowed&#xD;
&#xD;
               -  Must not be undergoing active treatment&#xD;
&#xD;
               -  Patients with prior bilateral mastectomy are eligible for study but not eligible&#xD;
                  for randomization&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female only&#xD;
&#xD;
          -  No psychiatric or cognitive disorder that would preclude giving informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Schwartz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lombardi Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

